SAN DIEGO, July 19, 2016 -- Access Scientific has introduced the POWERWAND™ XL, a companion to the POWERWAND ALL-IN-ONE. The new POWERWAND XL is designed specifically for clinicians who prefer to use a component-based, over-wire insertion technique similar to the Modified Seldinger Technique (MST) they currently use. The XL technique feels similar to the MST but has these distinct advantages:
- Improves clinical outcomes through atraumatic catheter insertion
- Designed to reduce risk of deep-vein thrombosis by up to 500%; no trimming of catheter necessary
- Reduces risk of back leaking; no peel-away sheath
- Guidewire extends fully so the catheter does not drag across the intima of the vessel
- Faster and safer because of fewer steps (see table below).
|
||||||||||
As with MST insertions, the XL insertion technique utilizes a 21-gauge safety needle and guidewire to access the vessel. The XL accelerates line placement and makes it safer compared to MST, by eliminating the need for a peelable introducer sheath. Instead, the proprietary POWERWAND XL dilator and catheter are inserted directly over the wire and into the bloodstream. This technique eliminates the sheath-related steps in MST that can be associated with such risks as bleeding, back-leaking, and vessel damage.
The ALL-IN-ONE is inserted with the Accelerated Seldinger Technique (AST), which also improves on the MST in speed, number of steps, and safety (see table below). Both ALL-IN-ONE and XL deliver the evidence based, best in class midline:
- Size: 4Fr and 5Fr
- Length: 8 and 10cm
- Infection Prevention: ZERO BSIs over 12,000 catheter-days
- High Flow: Capable of delivering large volumes rapidly, 130-180 ml/min
- Power Injectable: 325psi / 8ml per second
- Blood Drawable: Allows for blood draws in most patients, 60 – 99%
- Patient Satisfaction: Provides patients with one stick hospitalization
Insertion Technique Comparison: MST, AST, and XL
[table #1]
About Access Scientific, LLC
Access Scientific is dedicated to the development and commercialization of breakthrough, proprietary devices that make vascular access safer for patients and reduce the cost of care. The company pioneered the power-injectable midline market with the POWERWAND™. Made of proprietary ChronoFlex™ C, the POWERWAND midline has been the proven, evidence based, best-in-class, with over 12,000 catheter-days of published scientific data attesting to the lowest complication rate and highest completion-of-therapy rate of any vascular access device ever studied. The POWERWAND offers a unique approach to reducing hospital-acquired infections.
Photos accompanying this release are available at:
http://www.globenewswire.com/newsroom/prs/?pkgid=40876
http://www.globenewswire.com/newsroom/prs/?pkgid=40877
CONTACT: Liz Dowling, (415) 388-2794
Dowling & Dennis Public Relations
E-mail: [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Ford and Geely Explore Strategic Manufacturing Partnership in Europe
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 



